Year in Review

Overview

Journal Neurol Neuroimmunol Neuroinflamm

Specialty Neurology

Date 2019 Dec 14

PMID 31831570

Authors

Josep Dalmau

Marinos C Dalakas

Dennis L Kolson

Friedemann Paul

Scott S Zamvil

Affiliations

Soon will be listed here.

References

Armangue T, Sabater L, Torres-Vega E, Martinez-Hernandez E, Arino H, Petit-Pedrol M . Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurol. 2016; 73(4):417-24. PMC: 5823978. DOI: 10.1001/jamaneurol.2015.4607. View

Zamvil S, Slavin A . Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?. Neurol Neuroimmunol Neuroinflamm. 2015; 2(1):e62. PMC: 4309526. DOI: 10.1212/NXI.0000000000000062. View

Cortese A, Lombardi R, Briani C, Callegari I, Benedetti L, Manganelli F . Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2019; 7(1). PMC: 6935837. DOI: 10.1212/NXI.0000000000000639. View

Hoftberger R, Sepulveda M, Armangue T, Blanco Y, Rostasy K, Cobo Calvo A . Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2014; 21(7):866-874. PMC: 4824843. DOI: 10.1177/1352458514555785. View

Yednock T, Cannon C, Fritz L, Sanchez-Madrid F, Steinman L, Karin N . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992; 356(6364):63-6. DOI: 10.1038/356063a0. View

Rotstein D, Healy B, Malik M, Carruthers R, Musallam A, Kivisakk P . Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015; 2(6):e167. PMC: 4630683. DOI: 10.1212/NXI.0000000000000167. View

Kamtchum-Tatuene J, Mwandumba H, Al-Bayati Z, Flatley J, Griffiths M, Solomon T . HIV is associated with endothelial activation despite ART, in a sub-Saharan African setting. Neurol Neuroimmunol Neuroinflamm. 2019; 6(2):e531. PMC: 6340379. DOI: 10.1212/NXI.0000000000000531. View

Kupper C, Heinrich J, Kamm K, Bucklein V, Rothenfusser S, Straube A . Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. Neurol Neuroimmunol Neuroinflamm. 2019; 6(6):e628. PMC: 6807970. DOI: 10.1212/NXI.0000000000000628. View

Gill A, Kolson D . Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol. 2013; 33(4):307-59. PMC: 3753696. DOI: 10.1615/critrevimmunol.2013007247. View

10.

Yshii L, Hohlfeld R, Liblau R . Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol. 2017; 13(12):755-763. DOI: 10.1038/nrneurol.2017.144. View

11.

Patterson K, Iglesias E, Nasrallah M, Gonzalez-Alvarez V, Sunol M, Anton J . Anti-MOG encephalitis mimicking small vessel CNS vasculitis. Neurol Neuroimmunol Neuroinflamm. 2019; 6(2):e538. PMC: 6384022. DOI: 10.1212/NXI.0000000000000538. View

12.

Reindl M, Rostasy K . MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm. 2015; 2(1):e60. PMC: 4309525. DOI: 10.1212/NXI.0000000000000060. View

13.

Kim D, Hao J, Liu R, Turner G, Shi F, Rho J . Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS One. 2012; 7(5):e35476. PMC: 3342287. DOI: 10.1371/journal.pone.0035476. View

14.

Ekizoglu E, Baykan B, Sezgin M, Erdag E, Gundogdu-Unverengil G, Vanli-Yavuz E . Follow-up of patients with epilepsy harboring antiglycine receptor antibodies. Epilepsy Behav. 2019; 92:103-107. DOI: 10.1016/j.yebeh.2018.09.034. View

15.

Arino H, Gresa-Arribas N, Blanco Y, Martinez-Hernandez E, Sabater L, Petit-Pedrol M . Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol. 2014; 71(8):1009-16. PMC: 4841264. DOI: 10.1001/jamaneurol.2014.1011. View

16.

Ambrosius B, Gold R, Chan A, Faissner S . Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy. Neurol Neuroimmunol Neuroinflamm. 2019; 6(3):e551. PMC: 6501636. DOI: 10.1212/NXI.0000000000000551. View

17.

Cortese I, Muranski P, Enose-Akahata Y, Ha S, Smith B, Monaco M . Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2019; 380(17):1597-1605. DOI: 10.1056/NEJMoa1815039. View

18.

Knudsen A, Monstad S, Dorum A, Lonning P, Salvesen H, Drivsholm L . Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother. 2006; 55(10):1280-4. PMC: 11030605. DOI: 10.1007/s00262-006-0121-2. View

19.

Cordano C, Nourbakhsh B, Devereux M, Damotte V, Bennett D, Hauser S . pRNFL as a marker of disability worsening in the medium/long term in patients with MS. Neurol Neuroimmunol Neuroinflamm. 2019; 6(2):e533. PMC: 6340330. DOI: 10.1212/NXI.0000000000000533. View

20.

Graus F, Dalmou J, Rene R, Tora M, Malats N, Verschuuren J . Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997; 15(8):2866-72. DOI: 10.1200/JCO.1997.15.8.2866. View